Global Program Team (GPT) Medical Lead, and Global Medical Director for the Neurofibromatosis 1 (NF1) Rare Tumor Program. Team Lead for all KOSELUGO Externally Sponsored Clinical Research Studies. • Responsible for evaluating Externally Sponsored Collaborative research with GMAL that establish the clinical significance of KOSELUGO and determine alignment with strategic funding imperatives.• Responsible for Integrated Evidence Generation Plans.• Responsible for new launch planning as KOSELUGO medical Launch Lead.• Responsible for overseeing Merck-AstraZeneca Alliance medical affairs actions and joint medical plans.• Leads Global Tactical Planning by partnering with GMA, Business Operations, Patient Advocacy, GHEOR, Market Access and Scientific Communications.• Partners with Global Commercial Lead to develop long-range Global Strategic Plan including insights, strategic imperatives, and key initiatives, and presents to Executive Leadership Team and CEO.• Partners with Global Product Team Lead for creation of Life-Cycle Management Strategies.

Medical affairs expert conveying scientific and medical information to leading health care professionals for the purpose of ensuring safe and effective use of products. • Responsible for engagement and scientific exchange for KANUMA, and lysosomal acid lipase deficiency (LAL-D), a rare metabolic liver disease.• Led symposium planning including creating presentations, training speakers, and managing budget for major US congresses.• Identified clinical trial sites and evaluated potential investigators for studies and medical and commercial speaker programs.• Evaluated investigator-sponsored studies and potential collaborations in preclinical and clinical research in rare rheumatologic, and hepatic diseases.

-Biotechnology and pharmaceutical Search and Evaluation Lead-Analyst and Advisor for buy and sell side transactions

Rare Diseases Metabolics Team in Global Medical Affairs (Associate Director) Identifies clinical trial sites, and evaluates potential investigators for studies, and ad boards, and speaker programs. Evaluation of investigator sponsored studies and potential collaborations in preclinical and clinical research. Communication driver for thought leader engagement in field and congress activities.

Rare Diseases Cardiopulmonary Team Medical Affairs-Supported the safe and effective use of FDA-approved products through education and thought leader engagement.-Established relationships with key thought leaders in territory fostering a peer to peer level of exchange of medical information.-Supported Investigator-initiated research-Supported Life Cycle management of rare disease PH therapy including site communication and trial awareness programs.-Collaborated with internal and external stakeholders following company compliance guidelines.-Educated team regarding database management of thought leaders.

Ophthalmology Team Medical Affairs-Established and fostered scientific relationships with opinion leaders regarding disease-state and product-specific information. -Served as primary liaison with investigators interested in developing and performing investigator initiated research. -Documented and forwarded reports of adverse events to ensure safe and effective use of products. -Attended and provided scientific support of Medical Affairs activities and scientific sessions at regional and national congress meetings.

Established relationships with over 60 academic investigators and clinicians to discuss research findings and inventions. Evaluated technologies for patentability, and out-licensing. Created marketing materials and marketed university technologies to large pharma and small biotech companies. Maintained patent prosecution oversight for university intellectual property. Reviewed, edited, managed, and negotiated license agreements and institutional contracts.

Directed project management through the maintenance of productive relationships with strategic consultants, key opinion leaders , and interdepartmental project teamsEstablished and fostered relationships with the U.S. Government through direction of BioCryst communications to the U.S. Department of Health and Human Services (HHS) Established project timelines for HHS contract and served as Vice-Chair on the Peramivir Project Steering Committee

Prepared presentations for clinical investigator meetingsPresented preclinical and Phase I and Phase 2 clinical peramivir data to clinicians, pharmaceutical corporations, NIAID/NIH, Korean regulatory agencies, and the International Bird Flu Summit delegationPrepared clinical and nonclinical FDA documentation for pharmaceuticals in developmentWorked with consultants and members of the Board of Directors to construct and submit RFI and RFP documentsEstablished and coordinated nonclinical and clinical projects by cultivating relationships with KOLsConstructed and monitored timelines by integrating clinical, regulatory, CMC nonclinical, and analytical components to proactively manage the peramivir projectReviewed and edited press releases, participated in analyst and press interviews

Attended FDA meetings for pre-IND discussions. and developed relationships with clinical and nonclinical investigators at WHO and NIAID.Created scientific marketing materials for corporate business development opportunities.Developed and performed pharmacology studies to evaluate the potency and efficacy of peramivir, as well as other oncology and anticoagulant/anti-inflammatory investigational compounds.Participated in lead drug candidate identification and optimization.Principal Investigator for SBIR grant.Authored and reviewed manuscripts for publication.Trained and supervised laboratory technicians.